Dr Shah
Module 1: Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML
Hochhaus A et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51. Abstract
Module 3: Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment
Flygt H et al. Treatment-free remission after a second TKI discontinuation attempt in patients with chronic myeloid leukemia re-treated with dasatinib - interim results from the DAstop2 trial. Leukemia 2024;38(4):781-7. Abstract
Mahon F-X et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11(11):1029-35. Abstract
Dr Tinsley-Vance
Module 1: Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML
Cortes JE et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: Expert panel review. J Hematol Oncol 2018;11(1):143. Abstract
Cortes JE et al. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: Identification and management. Clin Lymphoma Myeloma Leuk 2017;17(2):78-82. Abstract
Jabbour E et al. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25(2):201-10. Abstract
Kwaśnik P, Giannopoulos K. Treatment-free remission—A new aim in the treatment of chronic myeloid leukemia. J Pers Med 2021;11(8):697. Abstract
Mohanavelu P et al. Meta-analysis of gastrointestinal adverse events from tyrosine kinase inhibitors for chronic myeloid leukemia. Cancers (Basel) 2021;13(7):1643. Abstract
Module 2: Role of Asciminib for Newly Diagnosed CP-CML
Atallah EL et al. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: The ASC2ESCALATE phase II trial. Future Oncol 2024;20(38):3065-75. Abstract
Combes FP et al. Dose justification for asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet 2024;63(9):1301-12. Abstract
Geissler J et al. Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries. J Cancer Res Clin Oncol 2017;143(7):1167-76. Abstract
Dr Mauro
Module 2: Role of Asciminib for Newly Diagnosed CP-CML
Bower H et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34(24):2851-7. Abstract
Cortes JE et al. Asciminib (ASC) demonstrates favorable safety and tolerability compared with each investigator-selected tyrosine kinase inhibitor (IS TKI) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the pivotal phase 3 ASC4FIRST study. ASH 2024;Abstract 475.
Hochhaus A et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med 2024;391(10):885-98. Abstract
Huang X et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118(12):3123-7. Abstract
Module 4: Management of CP-CML After Failure of Initial Therapy
Cortes J et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial. Blood 2021;138(21):2042-50. Abstract
Deininger MW et al. Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the Optic trial. ASH 2021;Abstract 307.
Hochhaus A et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: Longer-term follow-up of ASCEMBL. Leukemia 2023;37(3):617-26. Abstract
Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol 2023;98(9):1350-3. Abstract
Mauro MJ et al. Sustained efficacy and safety with asciminib (ASC) after almost 4 years of median follow-up from Ascembl, a phase 3 study of ASC vs bosutinib (BOS) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): An end of study treatment (EOS Tx) update, including results from switch population. ASH 2023;Abstract 4536.
Rea D et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. ASCO 2022;Abstract 7004.
Rea D et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: Wk 96 update. EHA 2022;Abstract S155.
Réa D et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021;138(21):2031-41. Abstract
Yeung DT et al. Asciminib: A new therapeutic option in chronic-phase CML with treatment failure. Blood 2022;139(24):3474-9. Abstract